Related references
Note: Only part of the references are listed.Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab
Gang Chen et al.
BMC MEDICINE (2012)
Depletion of HDAC6 Enhances Cisplatin-Induced DNA Damage and Apoptosis in Non-Small Cell Lung Cancer Cells
Lei Wang et al.
PLOS ONE (2012)
Loss of Activating EGFR Mutant Gene Contributes to Acquired Resistance to EGFR Tyrosine Kinase Inhibitors in Lung Cancer Cells
Keisuke Tabara et al.
PLOS ONE (2012)
Influence of RT-qPCR primer position on EGFR interference efficacy in lung cancer cells
Gang Chen et al.
BIOLOGICAL PROCEDURES ONLINE (2011)
Current progress of siRNA/shRNA therapeutics in clinical trials
John C. Burnett et al.
BIOTECHNOLOGY JOURNAL (2011)
Biomarker Analyses and Final Overall Survival Results From a Phase III, Randomized, Open-Label, First-Line Study of Gefitinib Versus Carboplatin/Paclitaxel in Clinically Selected Patients With Advanced Non-Small-Cell Lung Cancer in Asia (IPASS)
Masahiro Fukuoka et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Development of Quantitative Molecular Clinical End Points for siRNA Clinical Trials
Robyn P. Hickerson et al.
JOURNAL OF INVESTIGATIVE DERMATOLOGY (2011)
EGFR Tyrosine Kinase Inhibitors Activate Autophagy as a Cytoprotective Response in Human Lung Cancer Cells
Weidong Han et al.
PLOS ONE (2011)
The role of the c-Met pathway in lung cancer and the potential for targeted therapy
Martin Sattler et al.
Therapeutic Advances in Medical Oncology (2011)
Quantification of epidermal growth factor receptor T790M mutant transcripts in lung cancer cells by real-time reverse transcriptase-quantitative polymerase chain reaction
Gang Chen et al.
ANALYTICAL BIOCHEMISTRY (2010)
Combined inhibition of IGFR enhances the effects of gefitinib in H1650: a lung cancer cell line with EGFR mutation and primary resistance to EGFR-TK inhibitors
Yun Jung Choi et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
MET Kinase Inhibitor SGX523 Synergizes with Epidermal Growth Factor Receptor Inhibitor Erlotinib in a Hepatocyte Growth Factor-Dependent Fashion to Suppress Carcinoma Growth
Yu-Wen Zhang et al.
CANCER RESEARCH (2010)
Phase I Trial of the Irreversible EGFR and HER2 Kinase Inhibitor BIBW 2992 in Patients With Advanced Solid Tumors
Timothy A. Yap et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
PTEN Loss Contributes to Erlotinib Resistance in EGFR-Mutant Lung Cancer by Activation of Akt and EGFR
Martin L. Sos et al.
CANCER RESEARCH (2009)
Cetuximab plus radiotherapy for the treatment of locally advanced squamous cell carcinoma of the head and neck
S. Griffin et al.
HEALTH TECHNOLOGY ASSESSMENT (2009)
The Cell Line Secretome, a Suitable Tool for Investigating Proteins Released in Vivo by Tumors: Application to the Study of p53-Modulated Proteins Secreted in Lung Cancer Cells
Jerome Chenau et al.
JOURNAL OF PROTEOME RESEARCH (2009)
Activation of MET by Gene Amplification or by Splice Mutations Deleting the Juxtamembrane Domain in Primary Resected Lung Cancers
Ryoichi Onozato et al.
JOURNAL OF THORACIC ONCOLOGY (2009)
Cetuximab plus chemotherapy in patients with advanced non-small-cell lung cancer (FLEX): an open-label randomised phase III trial
Robert Pirker et al.
LANCET (2009)
MET as a target for treatment of chest tumors
Nicole A. Cipriani et al.
LUNG CANCER (2009)
Gefitinib or Carboplatin-Paclitaxel in Pulmonary Adenocarcinoma.
Tony S. Mok et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Clinical efficacy of erlotinib in patients previously treated for advanced non-small cell lung cancer
Songwen Zhou et al.
RESPIROLOGY (2009)
A cell-based high-throughput screen for epidermal growth factor receptor pathway inhibitors
Wen-Hsing Lin et al.
ANALYTICAL BIOCHEMISTRY (2008)
Role of cMET expression in non-small-cell lung cancer patients treated with EGFR tyrosine kinase inhibitors
P. A. Zucali et al.
ANNALS OF ONCOLOGY (2008)
Caspase cleavage of the MET receptor generates an HGF interfering fragment
Julien Deheuninck et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2008)
Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer
Z. Tang et al.
BRITISH JOURNAL OF CANCER (2008)
A phase II pharmacodynamic study of erlotinib in patients with advanced non-small cell lung cancer previously treated with platinum-based chemotherapy.
Enriclueta Felip et al.
CLINICAL CANCER RESEARCH (2008)
Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023
Karen Kelly et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
MET gene copy number in non-small cell lung cancer: Molecular analysis in a targeted tyrosine kinase inhibitor naive cohort
Michele Beau-Faller et al.
JOURNAL OF THORACIC ONCOLOGY (2008)
Molecular mechanisms underlying the synergistic interaction of erlotinib, an epidermal growth factor receptor tyrosine kinase inhibitor, with the multitargeted antifolate pemetrexed in non-small-cell lung cancer cells
Elisa Giovannetti et al.
MOLECULAR PHARMACOLOGY (2008)
SiRNA targeting against EGFR, a promising candidate for a novel therapeutic application to lung adenocarcinoma
Sumitaka Yamanaka et al.
PATHOBIOLOGY (2008)
Modeling oncogene addiction using RNA interference
S. Michael Rothenberg et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Signaling networks assembled by oncogenic EGFR and c-Met
Ailan Guo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor I (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours
Falm Eskens et al.
BRITISH JOURNAL OF CANCER (2008)
MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib
James Bean et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling
Jeffrey A. Engelman et al.
SCIENCE (2007)
Combination of EGFRMER2 tyrosine kinase inhibition by BIBW 2992 and BIBW 2669 with irradiation in FaDu human squamous cell carcinoma
Christina Schuetze et al.
STRAHLENTHERAPIE UND ONKOLOGIE (2007)
Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer
Nasser Hanna et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
Allelic dilution obscures detection of a biologically significant resistance mutation in EGFR-amplified lung cancer
Jeffrey A. Engelman et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
A Phase I/II study of weekly high-dose erlotinib in previously treated patients with nonsmall cell lung cancer
Daniel I. Milton et al.
CANCER (2006)
Cell cycle effects of vinflunine, the most recent promising Vinca alkaloid, and its interaction with radiation, in vitro
C Simoens et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2006)
Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck
JA Bonner et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
Enhanced cytotoxicity induced by gefitinib and specific inhibitors of the Ras or phosphatidyl inositol-3 kinase pathways in non-small cell lung cancer cells
ML Janmaat et al.
INTERNATIONAL JOURNAL OF CANCER (2006)
Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies
Ting-Chao Chou
PHARMACOLOGICAL REVIEWS (2006)
Epidermal growth factor receptors harboring kinase domain mutations associate with the heat shock protein 90 chaperone and are destabilized following exposure to geldanamycins
T Shimamura et al.
CANCER RESEARCH (2005)
Erlotinib in previously treated non-small-cell lung cancer
FA Shepherd et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Sequence characteristics of functional siRNAs
B Jagla et al.
RNA (2005)
Functional expression and mutations of c-met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer
PC Ma et al.
CANCER RESEARCH (2005)
Rational siRNA design for RNA interference
A Reynolds et al.
NATURE BIOTECHNOLOGY (2004)
Guidelines for the selection of highly effective siRNA sequences for mammalian and chick RNA interference
K Ui-Tei et al.
NUCLEIC ACIDS RESEARCH (2004)
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
R Sordella et al.
SCIENCE (2004)
Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer
J Mendelsohn et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Share Paper
